HGH Fragment 176-191 vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
HGH Fragment 176-191Fat Loss & Metabolic
AOD-9604- Summary
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- ~30 minutes
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- SubQ
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 300-600 mcg
- Frequency
- 1–3 times daily
- Once daily
- Key Benefits
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —